Table 4.

Changes in other biochemical parameters from baseline between groups

Outcome	Placebo (n = 41)	Silymarin (n = 42)	P value
TG (mmol/L)
12 weeks	0.07 ± 0.28	0.29 ± 0.28	0.601
24 weeks	0.06 ± 0.41	0.29 ± 0.39	0.692
TC (mmol/L)
12 weeks	0.39 ± 0.13	0.52 ± 0.13	0.223
24 weeks	0.32 ± 0.12	-0.01 ± 0.11	0.059
HDL-C (mmol/L)
12 weeks	0.10 ± 0.02	0.08 ± 0.02	0.566
24 weeks	0.11 ± 0.03	0.06 ± 0.03	0.290
LDL-C (mmol/L)
12 weeks	0.26 ± 0.10	0.30 ± 0.10	0.799
24 weeks	0.38 ± 0.12	0.08 ± 0.12	0.096
ApoA1 (g/L)
12 weeks	0.08 ± 0.02	0.06 ± 0.02	0.637
24 weeks	0.09 ± 0.03	0.03 ± 0.02	0.157
ApoB (g/L)
12 weeks	0.07 ± 0.02	0.08 ± 0.02	0.848
24 weeks	0.07 ± 0.03	-0.02 ± 0.03	0.023
ApoA1/ApoB
12 weeks	-0.01 ± 0.03	-0.02 ± 0.03	0.776
24 weeks	0.01 ± 0.04	0.07 ± 0.03	0.252
FPG (mmol/L)
12 weeks	0.02 ± 0.11	-0.07 ± 0.10	0.570
24 weeks	0.08 ± 0.18	-0.10 ± 0.18	0.507
Insulin (μU/mL)
12 weeks	5.82 ± 1.68	1.92 ± 1.65	0.117
24 weeks	3.48 ± 1.63	-0.23 ± 1.55	0.119
HOMA-IR
12 weeks	1.36 ± 0.47	0.54 ± 0.47	0.239
24 weeks	0.82 ± 0.47	-0.17 ± 0.45	0.149
UA (μmol/L)
12 weeks	8.58 ± 14.80	1.21 ± 14.60	0.736
24 weeks	-35.3 ± 13.80	-42.50 ± 13.20	0.719
SOD (U/mL)
12 weeks	4.22 ± 1.74	3.41 ± 1.72	0.754
24 weeks	2.13 ± 1.95	2.32 ± 2.03	0.951
hsCRP (mg/L)
12 weeks	0.31 ± 0.34	0.17 ± 0.33	0.778
24 weeks	2.35 ± 1.87	0.09 ± 1.78	0.406

Data are presented as adjusted means ± SEs. One-way ANCOVA was used to compare the difference in changes from baseline after 12 and 24 weeks of intervention between the groups with adjustment for baseline age and AST/ALT, ApoA1 and SOD concentrations

Abbreviations: TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ApoA apolipoprotein A, ApoB apolipoprotein B, FPG fasting plasma glucose, HOMA-IR homeostasis model of insulin resistance, hsCRP high-sensitivity C-reactive protein; SOD, superoxide dismutase